MELBOURNE, Australia (BUSINESS WIRE) Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering
PRP Foundation Patent Receives Notice of Allowance from Canadian Intellectual Property Office & Method to Treat Cancer Stem Cells Granted by the US Patent & Trademark Office
Propanc Biopharma (PPCB) Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Propanc Biopharma, Inc. ("Propanc" or the "Company"), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP suppresses the TGF-? pathway and the tumor.
MELBOURNE, Australia (BUSINESS WIRE) Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering